Skip to main content
. 2016 Feb 24;7(13):16962–16974. doi: 10.18632/oncotarget.7655

Figure 3. High throughput screening (HTS) of endocrine disruptors identifies BPAP as an AR down-regulator in 22Rv1 cells.

Figure 3

A. Cluster dendrogram of the HTS performed in six cell lines treated for 24 hrs with the indicated compounds at 10μM, and then immunolabeled with an AR antibody. Heatmap represents AR nuclear levels (yellow = high, blue = low); B. chemical structure of BPA and BPAP; C–H. raw data from panel A) showing a direct comparison between BPA, BPAP and MDV3100; I-K) BPAP or BPA treatment (10μM for 24h) +/− hormonal stimuli (E2, dexamethasone or R5020) followed by immunolabeling for ERα I. GR J. or PR K. a: p<0.05 vs. vehicle; b: p<0.05 vs. DHT.